Biohit Oyj is a Finnish company which develops, manufactures, and markets biotech and diagnostics products for use in research and health care.
| Company type | Julkinen osakeyhtiö |
|---|---|
| Nasdaq Helsinki: BIOBV.B | |
| Industry | Medical equipment |
| Founded | 1988 |
| Founder | Osmo Suovaniemi |
| Headquarters | Helsinki, Finland |
Area served | Worldwide |
Key people | Osmo Suovaniemi (Founder and Chairman of the Board), Semi Korpela (President and CEO) |
| Products | Diagnostics and medical devices (Acetium products for acid free stomach and smoking cessation) |
| Total equity | €15.5 million (2019) |
Number of employees | 40 in Finland, 10 in subsidiaries |
| Website | www |
Summary
editBiohit was established in 1988 in Finland by Professor Osmo Suovaniemi (M.D., Ph.D.), previously known as the founder of Labsystems.[1][2] He stepped down from the CEO position in June 2011, but remains actively involved with the company through positions on several advisory boards. Biohit is a globally operating Finnish biotechnology company. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) has been quoted on NASDAQ OMX Helsinki since 1999, Small cap/Healthcare. Semi Korpela was appointed CEO in 2011.
Markets
editBiohit's two businesses are acetaldehyde-eliminating products and diagnostics. More than 90% of Biohit's sales occur outside Finland.[3]
Diagnostic tests
editThe diagnostic product range of Biohit includes the GastroPanel examinations, which are used to aid diagnosis of Helicobacter pylori infection and atrophic gastritis from a blood sample. They are also ideal tools for the identification of patients at increased risk of gastric cancer, peptic ulcer disease, gastroesophageal reflux disease (GERD), and deficiencies of vitamin B12, calcium, and iron. In addition to this, Biohit offers Quick tests for the detection of
- Lactose intolerance
- Helicobacter pylori infection
- Celiac disease
- Screening of colorectal cancer
Acetaldehyde binding products
editIn 2018 was launched a new, nicotine-free smoking cessation product, Acetium Lozenge.
Monoclonal antibodies
editBiohit also develops and manufactures monoclonal antibodies for research use and use as raw materials for the diagnostic industry.
Instruments
editAdopting a systems approach, Biohit also provides laboratory equipment, such as microplate instruments and automates, as well as liquid handling products to support Biohit ELISA tests.
Distribution network
editA network of 40 distributors, including 2 subsidiaries, in more than 40 countries is selling Biohit products. In the U.S. the official distributor is Bio Testing Supplies, a division of Avrio Genetics.[citation needed]
Research, development, and intellectual property
editBiohit spends roughly 30% of net sales on basic research each year and pursues an aggressive patenting strategy.[4]
References
edit- ^ Harriet Öster (8 October 1998). "Labsystems kasvaa suuren suojassa". Tekniikka & Talous. Retrieved 2009-11-15.[permanent dead link]
- ^ Osmo Suovaniemi, Helena Hentola (2004). "Aggressive Innovation and Patenting Strategy – the Way to Success and National Well-Being" (PDF). Biohit. Archived from the original (PDF) on 2011-11-10. Retrieved 2013-03-02.
- ^ Biohit Oyj. Annual Report 2019
- ^ Reuters. Overview of Biomet Oyj. [1]